A5057234169- Nanoplatforms for cancer theranostics
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Click Chemistry and Applications
- Nanoparticle-Based Drug Delivery
- Drug Transport and Resistance Mechanisms
- Barrier Structure and Function Studies
- MRI in cancer diagnosis
- Angiogenesis and VEGF in Cancer
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- Receptor Mechanisms and Signaling
- Online and Blended Learning
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Lanthanide and Transition Metal Complexes
- Cancer, Hypoxia, and Metabolism
- Pharmacological Receptor Mechanisms and Effects
- Cancer Treatment and Pharmacology
- Iron Metabolism and Disorders
- Photoacoustic and Ultrasonic Imaging
- Problem and Project Based Learning
- Trace Elements in Health
Texas Tech University
2009-2023
Texas Tech University Health Sciences Center
2009-2023
Harding University Main Campus
2016-2017
National Cancer Institute
2009-2013
Center for Cancer Research
2010-2013
Northeast Ohio Medical University
2013
West Texas A&M University
2010
The University of Texas MD Anderson Cancer Center
2010
Science Applications International Corporation (United States)
2009
Laboratory of Molecular Genetics
2009
Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten compromise gains made systemic chemotherapy. The blood-tumor barrier (BTB) is compromised many brain metastases; however, the extent which this influences chemotherapeutic delivery efficacy unknown. Herein, we answer question by measuring BTB passive integrity, drug uptake, anticancer vivo two models that metastasize preferentially brain.Experimental metastasis uptake...
Abstract Purpose: As chemotherapy and molecular therapy improve the systemic survival of breast cancer patients, incidence brain metastases increases. Few therapeutic strategies exist for treatment because blood-brain barrier severely limits drug access. We report pharmacokinetic, efficacy, mechanism action studies histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclinical model metastasis triple-negative cancer. Experimental Design: The 231-BR trophic subline...
Brain (central nervous system; CNS) metastases pose a life-threatening problem for women with advanced metastatic breast cancer. It has recently been shown that the vasculature within preclinical brain metastasis model markedly restricts paclitaxel delivery in approximately 90% of CNS lesions. Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) nanoconjugate (∼5 kDa) can passively diffuse across leaky blood-tumor barrier and then be taken up into cancer cells...
The blood-brain barrier (BBB) is a specialized vascular interface that restricts the entry of many compounds into brain. This accomplished through sealing endothelial cells together with tight junction proteins to prevent paracellular diffusion. In addition, BBB has high degree expression numerous efflux transporters which actively extrude back blood. However, when metastatic lesion develops in brain vasculature typically compromised increases passive permeability (blood-tumor barrier; BTB)....
Abstract Tumors residing in the central nervous system (CNS) compromise blood–brain barrier (BBB) via increased vascular permeability, with magnitude of changes dependent on tumor type and location. Current studies determine penetrability a cancer therapeutic by administering progressively larger molecules until cutoff is observed where little to no accumulation occurs. However, decades-old experimental work mathematical modeling document methods calculate both size opening (pore) solute...
For metastases in the central nervous system, angiogenesis enhances metastatic potential and promotes progression. Primary factors which drive vessel growth are VEGF angiopoietin-2. Preclinical models show inhibition of either factor reduces spread inhibits growth. This work sets out to answer two questions a preclinical mouse model. First, whether combined angiopoietin-2, passive permeability limits drug uptake into brain metastases; second, this burden brain. We observed combinatorial...
J. Neurochem. (2010) 115, 1495–1507. Abstract Endothelial tight junctions and efflux transporters of the blood–brain barrier (BBB) significantly limit brain accumulation many drugs, including protease inhibitors such as saquinavir. The cholinergic agonist nicotine is one most commonly used drugs in world incidence even higher human immune deficiency virus population (∼70%). We examined ability its primary metabolite cotinine to modify uptake saquinavir rats. Both at pharmacological...
Measurement of vascular density has significant value in characterizing healthy and diseased tissue, particularly brain where varies among regions. Further, an understanding vessel size helps distinguish between capillaries larger vessels like arterioles venules. Unfortunately, few cutting edge methodologies are available to laboratories rapidly quantify density. We developed a rapid microscopic method, which quantifies the numbers diameters blood brain. Utilizing this method we...
The need for maternal medications is a known barrier to breastfeeding. Though most are compatible with lactation, healthcare providers use abundant caution, often viewing and breastfeeding as mutually exclusive. A dual intervention of an educational webinar access mobile app lactation pharmacology was used enhance provider familiarity, confidence, knowledge in medication during Surveys were administered before, one week after, three months after the evaluate performance gap improvement....
Abstract Introduction: In cancer, vascular destabilization and angiogenesis enhance tumor growth, metastatic potential, correlate with poor patient outcome. A primary driver of is endothelial growth factor (VEGF), secreted by cells in response to decreased vessel density hypoxia; highly expressed breast cancer. secondary driver, angiopoietin-2 (Ang-2), activated hypoxia, induces upon Tie2 receptor binding. VEGF Ang-2 have shown independently synergistically induce angiogenesis. Preclinical...
Abstract Approximately 1 in 8 women will develop breast cancer. Of these women, a subset metastatic cancer, of which 10-16% brain metastases. Treatment options are limited. The blood-brain barrier (BBB) serves as physical barrier, limiting drug entry into the brain, well active efflux drugs by P-Glycoprotein, Breast Cancer Resistance Protein, and/or Multidrug Resistance-associated Protein located on capillary endothelial cell membranes composing BBB. Active remodeling occurs when cancer...
<p>Supplementary figures showing representative histology and tracer distribution in the brain tumor models.</p>
<div>Abstract<p>Tumors residing in the central nervous system (CNS) compromise blood–brain barrier (BBB) via increased vascular permeability, with magnitude of changes dependent on tumor type and location. Current studies determine penetrability a cancer therapeutic by administering progressively larger molecules until cutoff is observed where little to no accumulation occurs. However, decades-old experimental work mathematical modeling document methods calculate both size...
<div>Abstract<p>Tumors residing in the central nervous system (CNS) compromise blood–brain barrier (BBB) via increased vascular permeability, with magnitude of changes dependent on tumor type and location. Current studies determine penetrability a cancer therapeutic by administering progressively larger molecules until cutoff is observed where little to no accumulation occurs. However, decades-old experimental work mathematical modeling document methods calculate both size...
<p>Supplementary figures showing representative histology and tracer distribution in the brain tumor models.</p>
<div>Abstract<p><b>Purpose:</b> Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten compromise gains made systemic chemotherapy. The blood–tumor barrier (BTB) is compromised many brain metastases; however, the extent which this influences chemotherapeutic delivery efficacy unknown. Herein, we answer question by measuring BTB passive integrity, drug uptake, anticancer <i>in vivo</i> two models...
Supplementary Data from Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks
<div>Abstract<p><b>Purpose:</b> As chemotherapy and molecular therapy improve the systemic survival of breast cancer patients, incidence brain metastases increases. Few therapeutic strategies exist for treatment because blood-brain barrier severely limits drug access. We report pharmacokinetic, efficacy, mechanism action studies histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclinical model metastasis triple-negative...
<div>Abstract<p><b>Purpose:</b> Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten compromise gains made systemic chemotherapy. The blood–tumor barrier (BTB) is compromised many brain metastases; however, the extent which this influences chemotherapeutic delivery efficacy unknown. Herein, we answer question by measuring BTB passive integrity, drug uptake, anticancer <i>in vivo</i> two models...
<div>Abstract<p><b>Purpose:</b> As chemotherapy and molecular therapy improve the systemic survival of breast cancer patients, incidence brain metastases increases. Few therapeutic strategies exist for treatment because blood-brain barrier severely limits drug access. We report pharmacokinetic, efficacy, mechanism action studies histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclinical model metastasis triple-negative...